Prostate Cancer

Findings May Impact Treatment Options for Men with Cancer

Published in Cancer Weekly, September 4th, 1995

The following was released by the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan:

Physicians may soon be able to tell which of their patients with prostate cancer need aggressive treatment.

Researchers at Detroit's Barbara Ann Karmanos Cancer Institute have isolated a potential marker for determining the aggressiveness of human prostate cancer. Their work, published in the August [1995] issue of Urology, found that elevated levels of 12-LOX, an enzyme, may indicate poor prognosis.

"We found that tumors with high 12-LOX expression are likely to have high metastatic potential or are locally advanced tumors," said David...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry